By: Amy Abernethy, M.D., Principal Deputy Commissioner, Kaveeta Vasisht, M.D., Pharm.D., Acting Associate Commissioner for Womens Health, Office of Womens Health, and, CAPT Terri L. Cornelison, M.D., Ph.D., Chief Medical Officer and Director, Health of Women Program, Center for Devices and Radiological Health
For the past 25 years, the U.S. Food and Drug Administration's Office of Womens Health has forged a pathway fostering and supporting advancements in the health of women through its work across the agency and with stakeholders. Developments in science have advanced our understanding of the unique role that sex and gender play in health and disease. Sex refers to an individuals biological characteristics, stemming from chromosomal complement. Alternatively, gender refers to the social construct by which we define ourselves as woman, man or other.
The Office of Womens Health (the Office) was established in 1994 and throughout its history has protected and advanced the health of women through science, policy, education, and outreach, and has advocated for the inclusion of women in clinical trials. The Office achieves our mission through the foundational principle that Sex as a Biological Variable should be factored into research design, analysis, reporting, and education. Our work in womens health also reminds us that issues pertinent to women are relevant to many others.
The Office of Womens Health has led workshops and collaborated with other agencies, industry, professional associations, and advocacy groups to address issues that are critically important to the health of women. The Office has provided nearly $40 million in research funding supporting more than 380 womens health projects, including research on cancer, HIV, osteoporosis, and the number one killer of women, cardiovascular disease. In addition, the Office brings world renowned speakers to provide educational seminars to FDA staff on the importance of sex and gender considerations in regulatory science.
The Office of Womens Health also works to promote and secure the inclusion of women in clinical trials and identifies and monitors the progress of crosscutting and multidisciplinary womens health initiatives. Those initiatives include emerging public health issues that require additional study, including, for example, how sex and gender influence opioid and nicotine use.
Last year, in collaboration with the FDA's Center for Drug Evaluation and Research and itsCenter for Tobacco Products, the Office of Womens Health hosted a 2-day public meeting, Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender. This meeting addressed these important issues and spotlighted the influences of sex and gender that lead men and women to initiate and experience substance use disorders differently. The Office has published the conference proceedings and is funding research to better understand the public health impact of sex differences on the genetics of smoking-related illness.
The FDAs Office of the Commissioner recently designated the Office of Womens Health to serve on the Task Force on Research Specific to Pregnant and Lactating Women. Established in 2016 by the 21st Century Cures Act, the Task Force advises the Secretary of Health and Human Services (HHS) about gaps in knowledge and research on safe and effective therapies for pregnant and lactating women. In September 2018, the Task Force submitted its report and 15 recommendations to HHS and Congress. Because of its work, the Task Force was extended for another two years and the Office of Womens Health continues to provide leadership and guidance to the Task Force on the implementation of these recommendations.
To help guide ourwork in the many areas that affect womens health, the Office of Womens Health created the Womens Health Research Roadmap, which highlights research priority areas, including: advancing safety and efficacy of FDA-regulated products; improving clinical study design and analyses; using novel modeling and simulation approaches; advancing biomarker science; expanding data sources and analysis; improving health communications; and, using emerging technologies to support identification of sex differences.
To help measure the impact and outcomes of programmatic initiatives, the Office developed the Research Impact and Outcomes Framework, a first-of-its kind, metric-driven framework, whichenables the Office to evaluate research on conditions that affect women disproportionately, as well as studies on sex differences that impact the use of FDA-approved, cleared, or market authorized products. The Research Impact and Outcome Framework is used prospectively to evaluate research proposals under consideration for funding by the Office based on how well the research aligns with the Offices mission and research priorities. The frameworks retrospective metrics are used to evaluate and assign value to a projects impact on womens health from a regulatory perspective, to help the Office of Womens Health identify gaps in its research portfolio, and to help the Office determine future funding priorities.
In 2019, the Office of Womens Health funded research projects on pulmonary embolism, which is the blockage of blood flow to the lungs by blood clots, and a leading cause of maternal death,and the development of an artificially-intelligent virtual pregnant woman modeling suite to support regulatory decisions. Funding was also allocated to evaluate the labeling compliance of dietary supplements targeted specifically to women, as well as evaluation of potential contamination of products that contain live microbes, with special emphasis on pregnant women and lactating women, and infants.
The Office is also providing funding for malaria research, utilizing model-informed drug development to facilitate antimalaria dosing in pregnant women. Other research funded in 2019 includes research to address patient reported outcomes during breast cancer drug development, evaluating the clinical comparability of U.S. vs. non-U.S. clinical trial data for FDA-regulated medical devices for weight-loss treatment, and funding for research on the use of computational models to evaluate the safety and effectiveness of vaginal heat therapy devices.
Take Time to Care is one of the Office of Womens Health first public education programs. It is a multi-faceted program that disseminates FDA health education materials through outreach activities and collaborative partnerships with national womens health and health professional organizations, community and faith-based institutions, industry, universities, and other government agencies. Utilizing this outreach collaboration model, the Office of Womens Health developed and continues to implement national outreach campaigns, including such initiatives as the Diverse Women in Clinical Trials, the Use Medicines Wisely Campaign, the Pink Ribbon Sunday Mammography Awareness Initiative, and, the College Womens Health Campaign.
Ensuring women have access to safe medical products on the market and that these products meet their health care needs are top priorities for the FDA. In 2019, the FDAs Center for Drug Evaluation and Research (CDER) approved a variety of new therapies to help advance womens health. Notably, CDER approved a new targeted therapy for patients with a certain type of metastatic breast cancer, a new biologic drug to treat osteoporosis in certain postmenopausal women at high risk of breaking a bone, a new drug to treat premenopausal women with acquired, generalized hypoactive sexual desire disorder (low sexual desire), and the first FDA-approved drug specifically for the treatment of adult women with postpartum depression.
The FDAs Center for Devices and Radiological Health (CDRH) also recognizes that sex and gender may have considerable impact on health, and on interaction with medical devices. As we learn more about sex- and gender-based differences in the performance of medical devices and new innovations become a reality, we work to ensure that our policies continue to evolve with the current science.
In 2016, CDRH created its Health of Women Program to address the steadily growing importance of sex- and gender-specific issues that arise regarding medical technology design and development, clinical trial design, and other medical device-related matters.
In September, 2019, CDRH unveiled a new Health of Women Program Strategic Plan, and is seeking input from stakeholders to help shape its implementation. The CDRH Health of Women Program and its Strategic Plan extends beyond reproductive and gynecologic health. The approach is comprehensive it considers a womans entire body, including health conditions specific to women, conditions more common or more serious in women, distinct causes or manifestations in women, different outcomes or treatment options in women, and conditions with higher morbidity or mortality in women.
Through the Health of Women Program, CDRH researchers, reviewers, and analysts are considering how sex and gender are factored into research design, device development, and analyses of studies in humans, vertebrate animals, tissue cultures and primary cell lines.
This work being led by CDRH is an important step forward for the FDA. Along with other centers and offices across the FDA, it amplifies the Office of Womens Health foundational principle that considerations of sex and gender should be factored into research design, analysis, reporting and education.
The FDA takes very seriously its long-standing commitment and involvement in medical science and growth in our overall understanding of, and approach to, womens health. The absolute need for research, data, and insight that reflects the overall health of a woman and the foundational principle of Sex as a Biological Variable remains at the forefront of the work we do agency-wide in carrying out our mission to protect and promote public health.
FDA actions to protect womens health over the past quarter century are memorialized in the FDAs History Vault. Whether through accelerating an approval, removing a product from the market, or by issuing guidance on nutrition and dietary supplements, the FDA has used its regulatory authorities to advance womens health.
In honor of the 25th anniversary of the Office of Womens Health, the FDA History Office has created an exhibit highlighting the agencys long-standing commitment to protecting and promoting womens health. These historical artifacts and images are currently on display at the FDAs White Oak Campus in Silver Spring, Maryland, and can also be viewed remotely on FLICKR.
- Can you trust mHealth apps? Why transparency is a must - American Medical Association - November 18th, 2019
- Nisonic Demonstrates Automatic Measurements of Optic Nerve Sheath Diameter as a Marker for Increased Intracranial Pressure Using Transorbital... - November 18th, 2019
- How Is Nanotech Reshaping the Medical Technology Sector? - Medical Tech Outlook - November 18th, 2019
- David Crais of CMG Carealytics Invited to NASA Cross Industry Innovation Summit - Benzinga - November 18th, 2019
- Shadowless Lamps Market will be grow in the upcoming year with players Greetmed, Aeomed, Mindray, BenQ Medical Technology - Daily Market Insight - November 18th, 2019
- Global Oxygen Regulator Market Insights Report 2019-2025 : Precision Medical, Harris, Essex Industries, Acare Technology - Industry News Time 24 - November 18th, 2019
- Research Roundup: Peanut allergies, heart disease treatments and wearable technology - The Stanford Daily - November 18th, 2019
- Private health insurers accused of lying about costs to raise premiums - 7NEWS - November 18th, 2019
- Title Wearable technology in healthcare: What are the leading themes? - Medical Device Network - November 18th, 2019
- ITM and CIRC Sign Technology License Agreement for the Production and Distribution of Medical Radioisotopes in China - Business Wire - November 18th, 2019
- Freudenberg Medical Achieves Break-through in Measurement Technology for Silicone Tubes with Helix iMC - Business Wire - November 12th, 2019
- Bridging the gap: Using technology to maintain patient contact - Medical Economics - November 12th, 2019
- Want to know your mental health status? There's an app for that - CU Boulder Today - November 12th, 2019
- Gets Its Catalyst And Trades Up::Creative Medical Technology Holdings Inc, (OTC US:CELZ) - News Planets - November 12th, 2019
- The Russian Military Will Soon Assign Soldiers Based on Their "Genetic Passports" - The National Interest Online - November 12th, 2019
- Hospital Furnitures Market Strategic Insights 2019 with analysis of Leading players: Stryker, Bio Medical Solutions, GPC Medical, Chang Gung Medical... - November 12th, 2019
- Is Computer-Vision the New Ground-Breaking Technology in the... - Medical Tech Outlook - November 12th, 2019
- BD Submits Pre-Market Approval Supplement to FDA for BD Onclarity HPV Test with Extended Genotyping Capabilities - PRNewswire - November 12th, 2019
- Rumor Claims Olympus will Shut Down Its Camera Division Within a Year - PetaPixel - November 12th, 2019
- InVivo Therapeutics Announces Appointment of Robert Rosenthal to Board of Directors - OrthoSpineNews - November 12th, 2019
- Global Cardiology Information System (CIS) Market Key Players and Share by 2025| CREALIFE Medical Technology and others - Market News Reports - November 12th, 2019
- How to have the right sensor for your medical IoT job - Medical Design & Outsourcing - November 12th, 2019
- Synaptive Ventures To the Spinal Surgery Market with Modus V - Medical Tech Outlook - November 12th, 2019
- Why DuPont will be at both Medica and Compamed - Medical Plastics News - November 12th, 2019
- Insights from Cathy Burzik's 40 years in the healthcare industry - Medical Design & Outsourcing - November 10th, 2019
- New Stanford hospital to open one week from today - Scope - November 10th, 2019
- Community Bank of Raymore Takes Position in Stryker Co. (NYSE:SYK) - Polson News - November 10th, 2019
- Cannabis industry is drawing big-name investors in R.I. - The Providence Journal - November 10th, 2019
- Avita Medical share price on watch after being added to the ASX 200 - Yahoo Finance - November 10th, 2019
- Head to Head Survey: Apyx Medical (NASDAQ:APYX) and AdvanSource Biomaterials Corpration (NASDAQ:ASNB) - Riverton Roll - November 10th, 2019
- Why Medicine Needs a New Hippocratic Oathand What It Should Be - Singularity Hub - November 8th, 2019
- Global SMT Equipment Market 2019-2023: Progression in Self-Driven Cars, Growth in Medical Technology, Increasing Smart Home Spending, Budding... - November 8th, 2019
- How Is the Medical Industry Using Deep Learning? - Business.com - November 8th, 2019
- Latest trends in medical monitoring devices and wearable health technology - Business Insider India - November 8th, 2019
- American Headache Society Publishes Article Demonstrating the Promise of Remote Electrical Neuromodulation (REN) as First-Line Treatment for Acute... - November 8th, 2019
- Townsen Memorial Clinics Now Open in Houston and Humble - PR Web - November 8th, 2019
- Compamed 2019: Everything you need to know - Medical Plastics News - November 8th, 2019
- CannGoods bridging the gap between hemp growers and off-take customers with its new tech - Proactive Investors USA & Canada - November 8th, 2019
- Conformis Announces FDA Clearance and Full Commercial Launch of Next Generation Hip System at the 2019 AAHKS Conference - OrthoSpineNews - November 8th, 2019
- EMMAC Life Sciences expanding on its medical cannabis acquisitions in London, Portugal, and Spain - Proactive Investors USA & Canada - November 8th, 2019
- A snapshot of the global patent landscape in eight charts - IAM - November 8th, 2019
- Olympus Now the Exclusive Distributor of the RocaFlow Pump and Tubing Sets - The Reporter - November 5th, 2019
- Adam Ferrari Highlights the Treatments and Medical Technology for Spinal Injuries utilized by Next Steps of Chicago - PRUnderground - November 5th, 2019
- Axonics Responds to Patent Action by Medtronic - Business Wire - November 5th, 2019
- Four-Year Data From the IN.PACT Global Study Highlight Durable Performance and Safety of IN.PACT Admiral DCB - Vascular Disease Management - November 5th, 2019
- The 10 Luxury Wellness Escapes You'll Want to Book for 2020 - TownandCountrymag.com - November 5th, 2019
- Detection Technology Awarded ISO 13485-2016 Certification for Medical Flat Panel Detectors - Imaging Technology News - November 5th, 2019
- Europe Pacemakers Market to 2027 - Regional Analysis and Forecasts By Product Type, Technology, End User, and Country - ResearchAndMarkets.com -... - November 5th, 2019
- Cardiac Monitoring (CM) & Cardiac Rhythm Management (CRM) Devices Market Opportunities to 2024 - World Market Projected to Exceed $25 Billion by... - November 5th, 2019
- RAD Technology Medical Systems Collaborates with Vanguard Healthcare Solutions to Bring Mobile Radiotherapy to Europe - P&T Community - November 5th, 2019
- Misonix to Participate in Three Upcoming Investor Conferences - Associated Press - November 5th, 2019
- NYC Marathon Runners Turning To Intensive Medical Technology To Reach Peak Performance - CBS New York - October 28th, 2019
- Judge to hear motion aiming to temporarily shut down Newton County plant - CBS46 News Atlanta - October 28th, 2019
- 3Ms Shares Could Cross $200 Next Year Thanks To Acelity Acquisition - Forbes - October 28th, 2019
- Neuronetics and Success TMS Partner to Increase Patient Access to Leading Depression Treatment, NeuroStar Advanced Therapy - The Courier-Express - October 28th, 2019
- Medical Device Security Market Growth Analysis 2019 to Share Key Aspects of the Industry with the details of Influence Factors Forecast to 2024 -... - October 28th, 2019
- Where Are The Medical CIOs Investing? - Medical Tech Outlook - October 28th, 2019
- What We Know About the Man Accused of Stabbing His Mother to Death in a Plainville Kitchen - NBC10 Boston - October 28th, 2019
- Medical billing is a nightmare, but start-up Ooda is working to make it way easier, and some insurers are optimistic - CNBC - October 28th, 2019
- 10 Medical Advances That Will Shape the Future of Healthcare - Discover Magazine - October 28th, 2019
- OraSure simplifies medical testing worldwide. Why the CEO says theyre still based in Bethlehem. - lehighvalleylive.com - October 28th, 2019
- The real horror this Halloween is the FDA's drug approval process | TheHill - The Hill - October 28th, 2019
- These Apps Say You May Have a Health Disorder. What if Theyre Wrong? - The New York Times - October 28th, 2019
- Private health insurers say cost of medical devices putting pressure on premiums - The Guardian - October 28th, 2019
- Misonix to Report Fiscal 2020 First Quarter Financial Results and Host Conference Call and Webcast on November 7 - GlobeNewswire - October 28th, 2019
- GTX merges with NeuroRecovery Technologies to form GTX medical BV - Medical Device Network - October 28th, 2019
- The Future of Proton Beam Therapy - Nature World News - October 28th, 2019
- X-Ray Detectors Market Report Extensive Analysis 2019 | Specified by Production, Technology, Competition, and Revenue Forecast till 2024 - Elamal News - October 28th, 2019
- PhenoMx executes MOU to develop strategic initiatives for Thailand's biotech, life sciences and medical industries - The New Economy - October 28th, 2019
- Why collaboration is key for the medtech industry to deliver life-saving innovations - create digital - October 28th, 2019
- Members Move Medicine: Tackling the underlying barriers to care - American Medical Association - October 28th, 2019
- Microspheres Market 2019 | Remarkable Growth Factors with Industry Size & Share, New Innovations of Leading Players & Forecast till 2024 -... - October 28th, 2019
- Safe Orthopaedics Announces the Approvals of SteriSpine LC and CC in Japan - Business Wire - October 28th, 2019
- Axonics Broadens EU Commercial Footprint with Recommendation for Reimbursement in France and Supply Contract in Norway - Business Wire - October 7th, 2019
- Medtronic Initiates Worldwide Pivotal Study of a New Approach to Treating Dangerously Fast Heart Rhythms - GlobeNewswire - October 7th, 2019
- TE Connectivity Collaborates With Hanhaa and Avnet to Advance Smart Tracking - PRNewswire - October 7th, 2019
- CONMED Corporation to Announce Third Quarter 2019 Financial Results on October 30, 2019 - BioSpace - October 7th, 2019
- UI graduate student works to commercialize drug that prevents osteoarthritis - UI The Daily Iowan - October 7th, 2019
- Medical Technologist Job in Multiple Locations - Department of the Air Force - LemonWire - October 7th, 2019
- Artificial Joints Market Research and New Innovations in Medical Sector 2019 to 2025 - The Chicago Sentinel - October 7th, 2019